Spectral AI reported full-year 2025 research and development revenue of $19.7 million, driven by its DeepView AI platform. With a strengthened cash position of $15.4 million, the company has introduced its first revenue guidance for 2026 as it transitions toward commercialization.
Spectral AI has been awarded $31.7 million in non-dilutive funding from BARDA to accelerate the development and clinical validation of its DeepView® System. This investment aims to enhance AI-driven medical diagnostics for faster, more accurate wound care decisions, particularly in burn and diabetic foot ulcer management.
About BARDA coverage
This page surfaces every story mentioning BARDA across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
What you see
What it tells you
Story count
Number of distinct stories where BARDA was a primary or referenced actor.
Recency clustering
Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distribution
Aggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche links
When the same entity surfaces in our sibling networks, we link to those views to enrich context.